www.neurologiepropraxi.cz / Neurol. praxi. 2024;25(2):124-129 / NEUROLOGIE PRO PRAXI 129 PŘEHLEDOVÉ ČLÁNKY Terapie roztroušené sklerózy zaměřená na B‑lymfocyty: od teorie po dekádu ocrelizumabu v praxi 7. Elišák M. Ocrelizumab – dlouhodobé údaje o účinnosti a bezpečnosti v reálné klinické praxi u pacientů s relaps remitentní roztroušenou sklerózou. Neurol. praxi. 2022;23(3):233-237. 8. Engmann NJ, Sheinson D, Bawa K, et al. Persistence and adherence to ocrelizumab compared with other disease ‑modifying therapies for multiple sclerosis in U.S. commercial claims data. Journal of Managed Care & Specialty Pharmacy. 2021;27(5):639-649. https://doi.org/10.18553/JMCP.2021.20413. 9. Grillo‑López AJ. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Review of Anticancer Therapy. 2003;3(6):767-779. https://doi.org/10.1586/14737140. 3. 6.767. 10. Hauser SL, Bar‑Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2017;376(3):221-234. https://doi. org/10.1056/NEJMOA1601277. 11. Hauser SL, Kappos L, Montalban X, et al. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021;97(16):E1546–E1559. https://doi. org/10.1212/WNL.0000000000012700. 12. Hellwig K, Oreja‑Guevara C, Vukusic S, et al. Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database [P061]. 9th Joint ECTRIMS ACTRIMS Meeting. 2023. 13. Hrnciarova T, Drahota J, Spelman T, et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing ‑remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. Multiple Sclerosis and Related Disorders. 2023;76. https://doi.org/10.1016/J.MSARD.2023.104803. 14. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing ‑remitting multiple sclerosis: A phase 2, randomised, placebo ‑controlled, multicentre trial. The Lancet. 2011;378(9805):17791787. https://doi.org/10.1016/S0140-6736(11)61649-8. 15. Kappos L, Traboulsee A, Li DKB, et al. Ocrelizumab exposure in relapsing‑remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. Journal of Neurology. 2023. https://doi.org/10.1007/S00415023-11943-4. 16. Kim T, Brinker A, Croteau D, et al. Immune‑mediated colitis associated with ocrelizumab: A new safety risk. Multiple Sclerosis (Houndmills, Basingstoke, England). 2023;29(10):12751281. https://doi.org/10.1177/13524585231195854. 17. Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain A Journal of Neurology. 2012;135(Pt 10):2973-2979. https://doi. org/10.1093/BRAIN/AWS148. 18. Krejsek J. Biologika anti CD20 modulací zralých B lymfocytů účinně tlumí poškozující zánět u nemocných s roztroušenou sklerózou. Na způsobu podání biologika záleží? Remedia. 2023. 19. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England Journal of Medicine. 2017;376(3):30-31. https://doi. org/10.1056/NEJMOA1606468. 20. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population‑based register study. International Journal of Cancer. 2006;118(4):979984. https://doi.org/10.1002/IJC.21437. 21. Ochs J, Nissimov N, Torke S, et al. Proinflammatory CD20+ T cells contribute to CNS‑directed autoimmunity. Science Translational Medicine. 2022;14(638). https://doi.org/10.1126/ SCITRANSLMED.ABI4632. 22. Oksbjerg NR, Nielsen SD, Blinkenberg M, et al. Anti‑CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021; 52:102988. https://doi.org/10.1016/j.msard.2021.102988. 23. Simonsen CS, Flemmen HØ, Broch L, et al. Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population‑Based Registry. Frontiers in Neurology. 2021;12. https://doi.org/10.3389/FNEUR.2021.693017. 24. Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing‑Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurology. 2021;78(10):1197-1204. https://doi.org/10.1001/JAMANEUROL.2021.2738. 25. Stastna D, Drahota J, Lauer M, et al. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease‑modifying therapies were initiated from 2013 to 2021. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechia. 2023. https://doi.org/10.5507/BP.2023.015. 26. Šťastná D, Horáková D. Dekáda terapie cílené na B lymfocyty aneb adherence a perzistence okrelizumabu na jedničku. Multiple Sclerosis NEWS. 2023;9(2):23-28. 27. Stastna D, Menkyova I, Drahota J, et al. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Mult Scler Relat Disord. 2021;54:103-104. https://doi.org/10.1016/j. msard.2021.103104. 28. Stastna D, Menkyova I, Horakova D. Okrelizumab již od první ataky roztroušené sklerózy – milník v úhradových kritériích. Neurol. praxi. 2022;23(4):312-316. https:// doi.org/10.36290/neu.2022.030. 29. Šťastná D, Menkyová I, Horáková D. Vysoce účinná terapie již od první ataky – důležitý posun v léčbě roztroušené sklerózy? Neurol. praxi. 2023;24(1):40-44. https://doi. org/10.36290/NEU.2022.068. 30. Weber M, Kappos L, Hauser S, et al. The Patient Impact of 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long‑Term Data from the Phase III OPERA and ORATORIO Studies [Poster P302]. 9th Joint ECTRIMS ACTRIMS Meeting. 2023. ODBORNÝ GARANT: MUDr. Stanislav Voháňka, CSc., MBA POŘADATEL: Společnost SOLEN, s. r. o., ve spolupráci s Neurologickou klinikou LF MU a FN Brno, Neuromuskulárním centrem ERN POČET KREDITŮ 2 Registrace ZDARMA TERMÍN listopad 2023 až říjen 2024 dostupný na online.solen.cz Úskalí klasické imunosupresivní léčby ON LINE KURZ OBSAH KURZU Současná a nová léčba myastenie gravis: praxe a výzvy MUDr. Stanislav Voháňka, CSc., MBA, MUDr. Magda Horáková Eculizumab v terapii thymom-asociované myastenie MUDr. Magda Horáková, MUDr. Viktória Kokošová, prof. MUDr. Josef Bednařík, CSc., MUDr. Stanislav Voháňka, CSc., MBA Kazuistika k diskuzi – MUDr. Michaela Týblová, Ph.D. Farmakorezistentní myastenik s thymomem – MUDr. Jana Junkerová Novinky v léčbě myasthenia gravis – MUDr. Michaela Týblová, Ph.D.
RkJQdWJsaXNoZXIy NDA4Mjc=